Solbec completes Phase I psoriasis trial

Solbec Pharmaceuticals (ASX: SBP) has announced successful completion of its Phase I study of its devil's apple-derived drug Coramsine as a treatment for psoriasis.

Preliminary results from the trial, which incorporated two stages to look at the safety and tolerability in healthy individuals, plus a third stage to assess efficacy in ten patients with psoriasis, indicate that there were no treatment-related adverse events during the trial. The drug was administered in a cream formulation and in the efficacy stage of the trial, was compared to both placebo and to a standard treatment for psoriasis over a period of 56 days.

The company said efficacy results would be reported in the second quarter of this year, once the trial has been unblinded and data analysed.